Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

This review discusses recent findings on the mechanisms driving bullous pemphigoid, highlighting epitope spreading and the roles of regulatory T cells, and reports no new experimental results.

SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

This study found that women with early-onset androgenetic alopecia had higher aldosterone levels and blood pressure, suggesting a possible link to the increased prevalence of hypertension in this group.

This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.

In a testosterone-induced BPH rat model, this study found that ursolic acid treatment significantly reduced prostate weight and hormone levels, suggesting it may inhibit BPH development.

This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.

In this study, finasteride alone or combined with terazosin significantly reduced PSA levels in men with BPH, while terazosin alone did not affect PSA levels.

This study concluded that finasteride is a viable first-line treatment for moderate uncomplicated benign prostatic hyperplasia, particularly in patients with larger prostates, by significantly reducing acute urinary retention and the need for surgery.

This study found that finasteride significantly alters urinary steroid profiles, complicating the detection of steroid abuse in doping-control analysis by potentially causing false-negative results.

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This review found that 5α-reductase inhibitors are associated with slightly increased rates of sexual dysfunction, gynecomastia, and mood disorders, but the true significance and persistence of these effects remain unclear.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

This study concluded that finasteride may safely reduce prostate size and improve urinary symptoms for at least six years in men with benign prostatic hyperplasia, though further improvements beyond six months are unlikely.

This study found no clear evidence that finasteride negatively affects erectile function, though it does cause a reduction in ejaculatory volume and has potential implications for prostate cancer risk.

This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

This review examined studies on erectile dysfunction and 5 alpha-reductase inhibitors, concluding that these drugs do not significantly cause erectile dysfunction and emphasizing testosterone's importance over dihydrotestosterone in erectile function.

This article reviews the role of 5α-reductase in cutaneous hyperandrogenism and the potential of 5α-reductase inhibitors and antiandrogens in treating conditions like hirsutism and male-pattern baldness, reporting no clinical results.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that certain trichoscopic features like white peripilar sign, yellow dots, and scalp pigmentation are positively correlated with the severity of androgenetic alopecia in Chinese patients.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

In this study, men with AGA who took finasteride 5 mg daily for 24 months showed a significant increase in hair counts compared to those who received a placebo.

In this uncontrolled study, ivermectin treatment for scabies resulted in the resolution of symptoms and negative skin scrapings in most patients at follow-ups.

This study found that in anagen hair follicles, the basement membrane zone components showed decreased expression in the lower hair bulb, with a complete absence of BP230 at the dermal papilla junction, suggesting an incomplete hemidesmosome structure in these regions.